Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Theravance Bio Ord (NQ: TBPH ) 8.310 +0.250 (+3.10%) Streaming Delayed Price Updated: 4:00 PM EDT, Oct 11, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Theravance Bio Ord < Previous 1 2 3 4 5 6 Next > Unveiling 4 Analyst Insights On Theravance Biopharma September 16, 2024 Via Benzinga Cracking The Code: Understanding Analyst Reviews For Theravance Biopharma August 06, 2024 Via Benzinga TBPH Stock Earnings: Theravance Biopharma Beats EPS, Misses Revenue for Q2 2024 August 05, 2024 TBPH stock results show that Theravance Biopharma beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. Via InvestorPlace Mama's Creations, GameStop And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session June 12, 2024 Via Benzinga Sidoti Events, LLC's Virtual June Small-Cap Conference June 11, 2024 Via ACCESSWIRE Recap: Theravance Biopharma Q4 Earnings February 26, 2024 Via Benzinga A Preview Of Theravance Biopharma's Earnings February 23, 2024 Via Benzinga Theravance Biopharma Earnings Preview August 04, 2023 Via Benzinga TBPH Stock Earnings: Theravance Biopharma Beats EPS, Beats Revenue for Q1 2024 May 13, 2024 TBPH stock results show that Theravance Biopharma beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. Via InvestorPlace BTIG Research Predicts Over 118% Rally for These 3 Stocks April 15, 2024 Wall Street stock predictions can run wild but after the tech sector's gains, these stocks could be better places for your money. Via InvestorPlace Short-Squeeze Showdown: 3 Stocks Ready to Crush the Skeptics March 12, 2024 Although the bears see cynical opportunities, you can make give them a taste of their own medicine with these short-squeeze stocks. Via InvestorPlace Logitech Posts Q3 Results, Joins Coinbase And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session January 23, 2024 U.S. stock futures were mostly lower this morning, with the Dow futures falling around 20 points on Tuesday. Via Benzinga Topics Stocks Exposures US Equities Why Applied Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session January 05, 2024 Shares of Applied Therapeutics, Inc. Via Benzinga Earnings Scheduled For February 26, 2024 February 26, 2024 Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.23 per share on revenue of $477.73 million. Via Benzinga Why Is Lung Disease Focused Theravance Biopharma Stock Trading Lower Today? January 05, 2024 Theravance Biopharma Inc (NASDAQ: TBPH) announced results from the Phase 4 PIFR-2 study of Yupelri (revefenacin) inhalation solution, the only once-daily, nebulized long-acting muscarinic antagonist... Via Benzinga 12 Health Care Stocks Moving In Friday's Pre-Market Session January 05, 2024 Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday January 05, 2024 Pre-market stock movers are worth checking on Friday as we lay out all of the biggest stories worth keeping tabs on this morning! Via InvestorPlace Franklin Covey Shares Fall After Q1 Results, Joins Theravance Biopharma, Voyager Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session January 05, 2024 U.S. stock futures were lower this morning, with the Dow Jones futures falling around 50 points on Friday. Via Benzinga Topics Stocks Exposures US Equities 7 Short-Squeeze Stocks That Are Screaming for Speculation December 24, 2023 If you like to march to your own beat even against high pressure, these short-squeeze stocks could be right for you. Via InvestorPlace Week In Review: Legend Partners DLL3 CAR-T Candidate With Novartis In $1.2 Billion Deal November 18, 2023 Legend Biotech partnered its DLL3 CAR-T candidates to Novartis in a $1.2 billion agreement, with $100 million offered upfront. Novartis will own worldwide rights to develop, manufacture, and... Via Talk Markets Roblox, Under Armour, GoPro, Nuvei And Other Big Stocks Moving Higher On Wednesday November 08, 2023 U.S. stocks traded mostly lower, with the Nasdaq Composite falling around 20 points on Wednesday. Here are some big stocks recording gains in today’s session. Via Benzinga Topics Stocks Exposures US Equities Earnings Scheduled For November 7, 2023 November 07, 2023 Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter. Via Benzinga Stocks That Hit 52-Week Lows On Friday September 29, 2023 Friday's session saw 112 companies set new 52-week lows. Via Benzinga Takeda Moves Out From Licensing Agreement With Theravance Biopharma May 11, 2023 In its Q1 earnings release, Takeda Pharmaceutical Co Ltd (NYSE: TAK) said it agreed to discontinue further development of TAK-954 for post-operative gastrointestinal dysfunction and the parties'... Via Benzinga Earnings Scheduled For May 8, 2023 May 08, 2023 Companies Reporting Before The Bell • HNI (NYSE:HNI) is likely to report quarterly loss at $0.03 per share on revenue of $462.26 million. Via Benzinga Stocks That Hit 52-Week Lows On Friday September 15, 2023 Friday's session saw 169 companies set new 52-week lows. Via Benzinga Tiziana Life Sciences Has Only Fully Human Anti-CD3 mAB In Clinical Studies, Could Be Poised To Improve Care For Patients With Severe Multiple Sclerosis April 19, 2023 Tiziana Life Sciences (NASDAQ: TLSA), a London-based biotechnology company, is developing a first-in-class drug, Foralumab. Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) at the... Via Benzinga Theravance Biopharma Finally Shelves Failed JAK Inhibitor Program, Lays Off Staff February 28, 2023 Via Benzinga Irenic Sends Letter to Theravance Biopharma Regarding the Urgent Need for a Governance Overhaul, Capital Return and Strategic Review February 27, 2023 From Irenic Capital Management, LP Via Business Wire Earnings Scheduled For February 27, 2023 February 27, 2023 Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.14 per share on revenue of $505.61 million. Via Benzinga < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.